CV Sciences (CVSI) Change in Accured Expenses (2011 - 2026)
CV Sciences (CVSI) reported Change in Accured Expenses of $92000.0 for Q1 2026, up 118.93% on a YoY basis from $42022.6 in Q1 2025, and up 134.59% sequentially from -$266000.0 in Q4 2025.
CV Sciences (CVSI) Change in Accured Expenses (2011 - 2026) Analysis & Trends
CV Sciences (CVSI) has 16 years of Change in Accured Expenses data on file, last reported at $92000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses rose 118.93% year-over-year to $92000.0; the trailing twelve-month figure through Mar 2026 stood at -$764000.0 (up 14.83% YoY), and the FY2025 full-year result was -$1.3 million, down 187.37% from the prior year.
- Change in Accured Expenses improved to $92000.0 in Q1 2026, from -$266000.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $193000.0 in Q3 2023 to a low of -$563000.0 in Q3 2025.
- A 5-year average of -$193352.9 and a median of -$187000.0 in 2024 frame the typical range for Change in Accured Expenses.
- Peak annual rise in Change in Accured Expenses reached 144.37% in 2023, while the deepest fall reached 1155.0% in 2023.
- Tracing CVSI's Change in Accured Expenses over 5 years: stood at -$20000.0 in 2022, then sank by 1155.0% to -$251000.0 in 2023, then jumped by 141.04% to $103000.0 in 2024, then sank by 358.25% to -$266000.0 in 2025, then soared by 134.59% to $92000.0 in 2026.
- Business Quant data shows CVSI's Change in Accured Expenses at $92000.0 in Q1 2026, -$266000.0 in Q4 2025, and -$563000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 32.60 Bn | 30.66 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 27.53 Bn | 23.47 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.06 Bn | 20.91 Bn | 648.10 Mn | -12.70 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.32 Bn | 18.52 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | CV Sciences | 4.11 Mn | 3.80 Mn | 1.56 Mn | 92,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 92,000.00 |
| Mar 31, 2026 | 92,000.00 |
| Dec 31, 2025 | -266,000.00 |
| Dec 31, 2025 | -266,000.00 |
| Sep 30, 2025 | -563,000.00 |
| Sep 30, 2025 | -563,000.00 |
| Jun 30, 2025 | -27,000.00 |
| Jun 30, 2025 | -27,000.00 |
| Mar 31, 2025 | -486,000.00 |
| Mar 31, 2025 | -486,000.00 |
| Dec 31, 2024 | 103,000.00 |
| Dec 31, 2024 | 103,000.00 |
| Sep 30, 2024 | -327,000.00 |
| Sep 30, 2024 | -327,000.00 |
| Jun 30, 2024 | -187,000.00 |
| Jun 30, 2024 | -187,000.00 |
| Mar 31, 2024 | -56,000.00 |
| Mar 31, 2024 | -56,000.00 |
| Dec 31, 2023 | -251,000.00 |
| Dec 31, 2023 | -251,000.00 |